Severe Frostbite in Extreme Altitude Climbers
A 54-year-old American man summited Everest in May 2016. During descent, he realized that his hands and feet, particularly the right hand and right foot, were frozen. During the summit push, he used only his right hand to hold onto the ropes. He rewarmed his right hand and right foot at camp 4 (8000 m). The next day, he walked to camp 2 (6400 m) and was evacuated to Kathmandu. He was not sure if refreezing might have occurred during descent to camp 2. He had been taking 80 mg of aspirin, a potassium supplement, and a multivitamin daily, and an occasional acetazolamide. On admission, the right foot had black discoloration of all 5 toes extending up to the proximal phalanx, consistent with grade 3 injuries (Figure 1). Similar frostbite injuries were also noted in the second through fifth fingers of the right hand and third finger of the left hand consistent with grade 2 injuries of 5 digits (images of hands not shown). Technetium-99 scintigraphy done immediately after patient arrival (vascular phase only) showed no perfusion in the toes of the right foot, nor in the 5 affected fingers. Time from injury to iloprost was between 48 and 52 h. Iloprost infusion was started and continued for 5 d. He experienced symptoms of flushing and headaches during infusion that required dose reduction during the first 2 d and symptoms resolved. At 3 mo, 8 of 10 of his frostbitten digits were partially amputated (Figure 1, right foot only).
Authors
Prativa Pandey, MDa,,Correspondence information about the author MD Prativa PandeyEmail the author MD Prativa Pandey, Ravi Vadlamudi, MD, MPHb, Rashila Pradhan, MDGPa, Kishore R. Pandey, MRCPa, Alex Kumar, MBBSc,d, Peter Hackett, MDe,f
References
- Vadlamudi R, Murphy HA, Pandey P. Benefit of prostacyclin for severe frostbite at altitude in Nepal. Proceedings of the 14th Conference of the International Society of Travel Medicine (CISTM14) Quebec; May 24–28 2015; Quebec City, Canada. International Society of Travel Medicine; 2015:39.
- Bruen, K.J., Ballard, J.R., Morris, S.E., Cochran, A., Edelman, L.S., and Saffle, J.R. Reduction of the incidence of amputation in frostbite injury with thrombolytic therapy. (discussion 51–3)Arch Surg. 2007; 142: 546–551
- Twomey, J.A., Peltier, G.L., and Zera, R.T. An open-label study to evaluate the safety and efficacy of tissue plasminogen activator in treatment of severe frostbite. (discussion 4–5)J Trauma. 2005; 59: 1350–1354
- Gonzaga, T., Jenabzadeh, K., Anderson, C.P., Mohr, W.J., Endorf, F.W., and Ahrenholz, D.H. Use of intra-arterial thrombolytic therapy for acute treatment of frostbite in 62 patients with review of thrombolytic therapy in frostbite. J Burn Care Res. 2016; 37: e323–e334
- Cauchy, E., Cheguillaume, B., and Chetaille, E. A controlled trial of a prostacyclin and rt-PA in the treatment of severe frostbite. N Engl J Med. 2011; 364: 189–190
- Poole, A. and Gauthier, J. Treatment of severe frostbite with iloprost in northern Canada. CMAJ. 2016; 188: 1255–1258
- Hallam, M.J., Cubison, T., Dheansa, B., and Imray, C. Managing frostbite. BMJ. 2010; 341: c5864
- Handford, C., Buxton, P., Russell, K., Imray, C.E., McIntosh, S.E., Freer, L. et al. Frostbite: a practical approach to hospital management. Extrem Physiol Med. 2014; 3: 7
- Cauchy, E., Chetaille, E., Marchand, V., and Marsigny, B. Retrospective study of 70 cases of severe frostbite lesions: a proposed new classification scheme. Wilderness Environ Med. 2001; 12: 248–255
- Cauchy, E., Marsigny, B., Allamel, G., Verhellen, R., and Chetaille, E. The value of technetium 99 scintigraphy in the prognosis of amputation in severe frostbite injuries of the extremities: a retrospective study of 92 severe frostbite injuries. J Hand Surg Am. 2000; 25: 969–978
- Millet, J.D., Brown, R.K., Levi, B., Kraft, C.T., Jacobson, J.A., Gross, M.D. et al. Frostbite: spectrum of imaging findings and guidelines for management. Radiographics. 2016; 36: 2154–2169
- Barker, J.R., Haws, M.J., Brown, R.E., Kucan, J.O., and Moore, W.D. Magnetic resonance imaging of severe frostbite injuries. Ann Plast Surg. 1997; 38: 275–279
- McIntosh, S.E., Opacic, M., Freer, L., Grissom, C.K., Auerbach, P.S., Rodway, G.W. et al. Wilderness Medical Society practice guidelines for the prevention and treatment of frostbite: 2014 update. Wilderness Environ Med. 2014; 25: S43–S54
- Bruen, K.J. and Gowski, W.F. Treatment of digital frostbite: current concepts. J Hand Surg Am. 2009; 34: 553–554
- Cauchy, E., Davis, C.B., Pasquier, M., Meyer, E.F., and Hackett, P.H. A new proposal for management of severe frostbite in the austere environment. Wilderness Environ Med. 2016; 27: 92–99
- Kaukinen, S., Ylitalo, P., Pessi, T., and Vapaatalo, H. Hemodynamic effects of iloprost, a prostacyclin analog. Clin Pharmacol Ther. 1984; 36: 464–469
- Fitscha, P., Kaliman, J., O’Grady, J., and Sinzinger, H. In vivo modulation of platelet deposition on human atherosclerotic lesions by various antiaggregatory prostaglandins. Folia Haematol Int Mag Klin Morphol Blutforsch. 1988; 115: 443–446
- Della Bella, S., Molteni, M., Mocellin, C., Fumagalli, S., Bonara, P., and Scorza, R. Novel mode of action of iloprost: in vitro down-regulation of endothelial cell adhesion molecules. Prostaglandins Other Lipid Mediat. 2001; 65: 73–83
- Balzer, K., Bechara, G., Bisler, H., Clevert, H.D., Diehm, C., Heisig, G. et al. Reduction of ischaemic rest pain in advanced peripheral arterial occlusive disease. A double blind placebo controlled trial with iloprost. Int Angiol. 1991; 10: 229–232
- Arosio, E., Sardina, M., Prior, M., De Marchi, S., Zannoni, M., and Bianchini, C. Clinical and circulatory effects of Iloprost either administered for 1 week or 4 weeks in patients with peripheral obstructive arterial disease at Leriche-Fontaine stage III. Eur Rev Med Pharmacol Sci. 1998; 2: 53–59
- Vitale, V., Monami, M., and Mannucci, E. Prostanoids in patients with peripheral arterial disease: a meta-analysis of placebo-controlled randomized clinical trials. J Diabetes Complications. 2016; 30: 161–166
- Groechenig, E. Treatment of frostbite with iloprost. Lancet. 1994; 344: 1152–1153